Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation

NCT05469178 is registered in ClinicalTrials.gov with BerGenBio ASA as lead sponsor.

NCT NCT05469178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05469178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation
Lead sponsor
BerGenBio ASA
Phase
Phase 1/2
Overall status
Terminated
Start date
March 3, 2023
Completion date
April 3, 2025
Enrollment
26 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung